NAT (nucleic acid testing) tests lead US IVD (in vitro diagnostic) growth
This article was originally published in Clinica
Comfortable - rather than exciting - growth of the US market for in vitro diagnostics is expected in the coming years. A new report from the Freedonia group (Cleveland, Ohio), In Vitro Diagnostics, predicts market expansion averaging some 7% in each of the next three years, revenues reaching $12,690 million in 2005. Growth will be led by demand for nucleic acid testing, as knowledge of the human genome begins to yield diagnostic tools.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.